Xtacy Therapeutics Corp. Stock price
Equities
XTCY
CA98423G1072
Investment Management & Fund Operators
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 CAD | 0.00% | -11.11% | -11.11% |
Sales 2021 | - | Sales 2022 | - | Capitalization | 7.51M 10.18M |
---|---|---|---|---|---|
Net income 2021 | -3M -4.07M | Net income 2022 | -1M -1.36M | EV / Sales 2021 | - |
Net Debt 2021 | 50.91K 68.99K | Net Debt 2022 | 25.37K 34.37K | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.09
x | P/E ratio 2022 |
-3.97
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.2% |
1 week | -11.11% | ||
Current month | -20.00% | ||
1 month | -20.00% | ||
6 months | -60.00% | ||
Current year | -11.11% |
Managers | Title | Age | Since |
---|---|---|---|
Meris Kott
CEO | Chief Executive Officer | - | 17-11-29 |
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 19-04-09 |
Monita Faris
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 19-04-09 |
Mark Ireton
BRD | Director/Board Member | 67 | 17-05-11 |
Meris Kott
CEO | Chief Executive Officer | - | 17-11-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.04 | -11.11% | 10,000 |
24-03-25 | 0.045 | -35.71% | 30,000 |
24-03-22 | 0.07 | +55.56% | 3,000 |
24-03-21 | 0.045 | -10.00% | 20,000 |
24-03-20 | 0.05 | +11.11% | 10,000 |
Delayed Quote Canadian Securities Exchange, March 28, 2024 at 03:13 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-11.11% | 1.61M | |
+2.70% | 124B | |
+6.28% | 98.83B | |
+21.88% | 63.89B | |
+6.62% | 63.42B | |
+15.43% | 43.93B | |
+10.70% | 43.38B | |
+16.03% | 34.24B | |
+13.21% | 27.27B | |
-0.18% | 23.35B |